; or (ii) such substance is used or intended for use in animals other than humans as permitted under section 512(a)(4) of the Federal Food, Drug, and Cosmetic Act. (C) If any person prescribes, dispenses, distributes, manufactures, or imports xylazine for human use, such person shall be considered to have prescribed, dispensed, distributed, manufactured, or imported xylazine not subject to an exclusion under subparagraph (B). . (b) Placement of xylazine on schedule III Schedule III in section 202(c) of the Controlled Substances Act ( 21 U.S.C. 812(c) ) is amended by adding at the end the following: (f) Xylazine. . (c) ARCOS tracking Section 307(i) of the Controlled Substances Act ( 21 U.S.C. 827(i) ) is amended— (1) in the matter preceding paragraph (1)— (A) by inserting or xylazine after gamma hydroxybutyric acid ; (B) by inserting or 512 after section 505 ; and (C) by inserting respectively, after the Federal Food, Drug, and Cosmetic Act, ; and (2) in paragraph (6), by inserting or xylazine after gamma hydroxybutyric acid . (d) Report to Congress on xylazine (1) Initial report Not later than 1 year after the date of enactment of this Act, the Attorney General, acting through the Administrator of the Drug Enforcement Administration and in coordination with the Commissioner of Food and Drugs, shall submit to Congress a report on the prevalence of illicit use of xylazine in the United States and the impacts of such use, including— (A) where the drug is being diverted; (B) where the drug is originating; (C) whether any analogues to such drug present a substantial risk of abuse; (D) whether and to what extent the illicit supply of xylazine derives from the licit supply chain